Actively Recruiting
Open-label Study Evaluating Safety and Drug Effects of WVE-006 in Adults With Pi*ZZ Alpha-1 Antitrypsin Deficiency
Led by Wave Life Sciences USA, Inc. · Updated on 2026-10-19
48
Participants Needed
9
Research Sites
N/A
Total Duration
AI-Summary
What This Trial Is About
Researchers are studying the safety, tolerability, pharmacodynamics, and pharmacokinetics of WVE-006, an RNA editing oligonucleotide, in people with alpha-1 antitrypsin deficiency AATD who have the Pi*ZZ genetic variant. This open-label study includes single ascending dose and multiple ascending dose periods to better understand how the drug behaves in the body and its potential effects on this condition. Participants will receive different doses of WVE-006 in two periods first, a single ascending dose phase and then a multiple ascending dose phase. The study will monitor how the body absorbs and processes the drug over up to 36 weeks. The research aims to evaluate changes in serum M-AAT protein levels and measure drug concentrations in plasma during these treatment periods. Throughout the study, participants will undergo medical evaluations to assess safety and drug effects, including monitoring adverse events and blood tests to measure protein levels and drug amounts in the blood. The study will last up to 36 weeks, with ongoing assessments of safety and drug activity. Participants will be followed closely to gather information about how the treatment is tolerated and processed by the body.
CONDITIONS
Brief Title
A Phase 1b/2a, Open-label Single Ascending Doses and Multiple Ascending Doses Study in Participants With Pi*ZZ AATD
Research Team
C
Clinical Operations
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here